<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/27170BAD-BC94-44F1-9E3D-152745F86A7F"><gtr:id>27170BAD-BC94-44F1-9E3D-152745F86A7F</gtr:id><gtr:name>PsiOxus Therapeutics</gtr:name><gtr:address><gtr:line1>Cherwell Innovation Centre</gtr:line1><gtr:line4>Upper Heyford</gtr:line4><gtr:postCode>OX25 5HD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6FCEECD3-FD47-48D7-BC12-0463377A2437"><gtr:id>6FCEECD3-FD47-48D7-BC12-0463377A2437</gtr:id><gtr:name>Virttu Biologics</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:department>Barts Cancer Institute</gtr:department><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/D5337A10-AC8A-402A-8164-C5F9CC6B0140"><gtr:id>D5337A10-AC8A-402A-8164-C5F9CC6B0140</gtr:id><gtr:name>Queen Mary, University of London</gtr:name><gtr:address><gtr:line1>Mile End Road</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>E1 4NS</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/27170BAD-BC94-44F1-9E3D-152745F86A7F"><gtr:id>27170BAD-BC94-44F1-9E3D-152745F86A7F</gtr:id><gtr:name>PsiOxus Therapeutics</gtr:name><gtr:address><gtr:line1>Cherwell Innovation Centre</gtr:line1><gtr:line4>Upper Heyford</gtr:line4><gtr:postCode>OX25 5HD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6FCEECD3-FD47-48D7-BC12-0463377A2437"><gtr:id>6FCEECD3-FD47-48D7-BC12-0463377A2437</gtr:id><gtr:name>Virttu Biologics</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C80FA399-9F25-4473-8481-C60F0F3D5D18"><gtr:id>C80FA399-9F25-4473-8481-C60F0F3D5D18</gtr:id><gtr:name>Cancer Research UK Cambridge Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A"><gtr:id>2512972D-6FE3-48FC-8B6B-CBD2BA6CE18A</gtr:id><gtr:name>Missouri University of Science and Tech</gtr:name><gtr:address><gtr:line1>Missouri University of Science and Tech</gtr:line1><gtr:line2>1870 Miner Circle</gtr:line2><gtr:line4>Rolla</gtr:line4><gtr:line5>Missouri</gtr:line5><gtr:postCode>MO 65409</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/F180C115-635C-42DD-A5A3-EB11559B15E2"><gtr:id>F180C115-635C-42DD-A5A3-EB11559B15E2</gtr:id><gtr:firstName>Iain</gtr:firstName><gtr:otherNames>Alexander</gtr:otherNames><gtr:surname>McNeish</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G0601891"><gtr:id>48E6D236-0147-4440-9F64-FF157B0E2472</gtr:id><gtr:title>Oncolytic adenoviral gene therapy for ovarian cancer</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>G0601891</gtr:grantReference><gtr:abstractText>We are trying to develop new treatments for ovarian cancer using oncolytic viruses. These are common viruses that are altered so that they destroy cancer cells by multiplying within them, but cannot multiply within normal human tissues. Our virus, dl922-947, is derived from an adenovirus, which is very common in the UK population and, under most circumstances, causes only a ?flu-like illness, even in its natural, active state. 
Our research has shown that dl922-947 has considerable potential as a treatment for ovarian cancer. A trial in women with recurrent ovarian cancer will commence in 2009. We now wish to improve the anti-cancer effect of dl922-947. 
Our results suggest that dl922-947 can work well in partnership with paclitaxel, a chemotherapy drug commonly used in ovarian cancer, but we wish to understand why, and whether other chemotherapy drugs may also combine well. We also want to understand how the immune system responds to dl922-947 in the abdominal cavity, where ovarian cancer grows. Finally, we will explore why some ovarian cancer cells do not respond well to dl922-947, by studying the patterns of gene expression in sensitive and resistant cells, especially genes that control cell division. Ultimately, this research could lead to more effective treatments for women with ovarian cancer.</gtr:abstractText><gtr:technicalSummary>Background
Oncolytic adenoviruses are promising new treatments for ovarian cancer. The E1A-CR2 deleted vector dl922-947 replicates selectively in tumour cells with abnormal Rb pathway function. The first clinical trial will commence in 2007. Further development of oncolytic adenoviruses depends upon identification of points in three key stages of the virus life cycle that can be manipulated for therapeutic benefit. An understanding of the role of the immune system in viral clearance from the abdomen is also vital for clinical application of these adenoviruses in ovarian cancer.

Aims and objectives
To improve viral anti-cancer activity by: 
1. maximising infectivity by investigating the interaction between dl922-947 and microtubules.
2. increasing viral replication by manipulating genes that are associated with resistance. 
3. augmenting the programmed cell death pathways activated by the virus using chemotherapy.
4. generating an immunocompetent murine model of ovarian cancer that supports adenovirus replication.

Design and Methods
The effects of the microtubule-active chemotherapy drugs paclitaxel, epothilone and vinblastine on dl922-947 infectivity will be examined using GFP-fluorescence assays and confocal microscopy. Their effects on cell death pathways will be examined in cytotoxicity assays in vitro and xenograft models in vivo. Cell cycle-regulated genes, including cyclin D2, p18, cdk2, cdc25A and survivin, may be critical regulators of viral activity. Their expression will be knocked down in ovarian cancer cells resistant to dl922-947 using RNA interference (RNAi) and the effects on replication and cytotoxicity examined. Ovarian cancer cells will also be transfected with nuclear-targeted survivin constructs and examined for alterations in cell survival and pRb phosphorylation. Immortalised ovarian surface epithelial cells with both normal and abnormal Rb pathway function will be used to validate results. Phosphatidylinositol 3?-kinase (PI3K) m play a key survival role following adenoviral infection. Using specific inhibitors and RNAi, the effects of PI3K pathway inhibition on dl922-947 function will be studied, in particular the role of PI3K in the cellular autophagic response. Finally, using a wholly murine system, the effects of intact immune function on adenoviral activity will be studied, particularly the role of T cell and macrophage-mediated viral clearance from the peritoneal cavity. 

Future opportunities
The research in this Fellowship will shape future clinical trials of oncolytic adenoviral vectors by identifying ideal chemotherapy/virus combinations. It will also highlight parameters in ovarian cancer that predict for the activity of a novel therapy targeted to the critical G1-S checkpoint that is frequently abnormal in this disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-09-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2007-10-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>1650008</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen Mary University of London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Barts and The London School of Medicine and Dentistry</gtr:department><gtr:description>Role of inflammatory cytokine-induced inflammation in the efficacy of oncolytic adenoviruses</gtr:description><gtr:id>A295912A-A484-42EE-A501-DEA15FBF19C4</gtr:id><gtr:impact>Oral presentations at NCRI and Ovarian Cancer Action conferences. Manuscript published in Molecular Therapy. Further grant applications pending</gtr:impact><gtr:outcomeId>42C3B8FDBC1-1</gtr:outcomeId><gtr:partnerContribution>Through this collaboration, I have started to work with Professor Balkwill on developing further clinical trials of anti-cytokine therapy in ovarian cancer</gtr:partnerContribution><gtr:piContribution>I shared a post-doc with Professor Balkwill - she and her team provide expertise on cytokine biology in ovarian cancer. My team and I provide expertise on adenovirus biology</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cancer Research UK Cambridge Institute</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>BriTROC</gtr:description><gtr:id>16CC0274-2240-4724-9951-4B213F546DB9</gtr:id><gtr:impact>Project comments on October 1st 2012, so it's a little early for outputs.</gtr:impact><gtr:outcomeId>KmiuS1caxPo-1</gtr:outcomeId><gtr:partnerContribution>See above</gtr:partnerContribution><gtr:piContribution>Established BriTROC., the UK ovarian cancer translational collaborative with James Brenton from CRI. Obtained &amp;pound;400,000 from Ovarian Cancer Action to fund BriTROC1 project.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>PsiOxus Therapeutics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>PsiOxus</gtr:description><gtr:id>28AC355F-E408-42A5-9A5D-9253F54366E4</gtr:id><gtr:impact>Trial is due to open in Jan 2014</gtr:impact><gtr:outcomeId>RNhjwrD3o8p-1</gtr:outcomeId><gtr:partnerContribution>PsiOxus are part-funding the trial and acting as sponsor</gtr:partnerContribution><gtr:piContribution>PsiOxus made an application to the Technology Strategy Board for funding for a phase I trial of their oncolytic virus ColoAd1 in relapsed ovarian cancer. I will be chief investigator on this trial</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Virttu Biologics</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Virttu</gtr:description><gtr:id>73B86D54-0393-42A2-9E64-0DF073FDEC03</gtr:id><gtr:impact>Again, this collaboration is still very new</gtr:impact><gtr:outcomeId>W5C2jmTJvwB-1</gtr:outcomeId><gtr:partnerContribution>Virttu will supply HSV vectors and training in HSV assays at their labs</gtr:partnerContribution><gtr:piContribution>This is a collaboration with a Glasgow-based SME which has generated an oncolytic HSV vector that will be evaluated pre-clinically in my lab with a view to clinical trials application</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited seminar at Imperial College</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>37A6E9C6-9076-4D87-B77A-F6E424199D47</gtr:id><gtr:impact>Audience of about 60 scientific and medical cancer researchers. Positive feedback from seminar series organisers

No subsequent impact</gtr:impact><gtr:outcomeId>9817ED3F530</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>NCRI Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>94C1BEA4-95C0-4D31-8D90-0CA7B2DD7D01</gtr:id><gtr:impact>Invited talk to the ovarian cancer session of the 2008 NCRI Conference in Birmingham.

Probably a little too soon to tell, but excellent potential collaborations set up with researchers in Cambridge and Vancouver</gtr:impact><gtr:outcomeId>F0683BF6B20</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to Queen Mary Trials Users' Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>7D29E181-C450-480E-910A-1C33426CEF54</gtr:id><gtr:impact>In the Institute of Cancer, we have established a trials users' group, which is a panel of cancer patients and other interested lay members. The role of the group is to look at Patient Information used in patient research initiated at Barts. I spoke about the process of translating laboratory research in clinical trials and also about the importance of collecting primary tissue for research purposes..

The group now meets twice per year in person and has approved information for the proposed ovarian cancer tissue bank.</gtr:impact><gtr:outcomeId>C2345B8093B</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Oral presentation at 1st Ovarian Cancer Action Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>7BEF3057-CBED-4237-841F-E4F49A6E5D76</gtr:id><gtr:impact>Oral presentation at the UK's first (and so far only) ovarian cancer meeting. Audience of &amp;gt;250 ovarian cancer researchers (both scientific and medical). Excellent feedback from organisers.

Useful discussions on adenovirus biology with researchers involved in previous gene therapy trials</gtr:impact><gtr:outcomeId>CFE9B823815</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2008</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentation to NCRN Consumer Liaison Group</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>D8AA531B-7E18-4774-AF3C-F344FF456F56</gtr:id><gtr:impact>Describing the difficulties in setting up early phase clinical trials to an audience of highly motivated members of a patient/consumer liaison group

They have invited me back.....</gtr:impact><gtr:outcomeId>0A6A6CD1BE8</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2009</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>90000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Queen Mary University of London PhD studentship</gtr:description><gtr:end>2014-08-02</gtr:end><gtr:fundingOrg>Queen Mary University of London</gtr:fundingOrg><gtr:id>9D3A0687-CE1A-4013-BD73-D8300456D628</gtr:id><gtr:outcomeId>JMYEAkjm5Xn0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>180000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Clinical Research Training Fellowship</gtr:description><gtr:end>2010-07-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>176D9743-11A0-46D2-A3C3-639FF7362B20</gtr:id><gtr:outcomeId>76AFC1B3AB30</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2007-08-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>BriTROC1 - Project grant</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>Ovarian Cancer Action</gtr:fundingOrg><gtr:fundingRef>62147/1</gtr:fundingRef><gtr:id>69E1C0F4-38D1-4BED-BC50-C9C572E6DB5E</gtr:id><gtr:outcomeId>TA5Fqaohh1a</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2012-12-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Wellcome Clinical Research Training Fellows</gtr:description><gtr:end>2017-09-02</gtr:end><gtr:fundingOrg>Wellcome Trust</gtr:fundingOrg><gtr:fundingRef>WT102746AIA</gtr:fundingRef><gtr:id>1EF50B85-C1D8-40FA-B5E8-E748A624BDF2</gtr:id><gtr:outcomeId>5463b6e2e0f992.82670769</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>120000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC University of Glasgow Doctoral Training Programme</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>University of Glasgow</gtr:fundingOrg><gtr:id>29362E53-7DB9-476D-9644-67AF6CA0237E</gtr:id><gtr:outcomeId>54612ebf75c594.94146295</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>1400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Programme grant</gtr:description><gtr:end>2018-01-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>2575075C-C3A6-44A4-9169-5D3F928BC7D9</gtr:id><gtr:outcomeId>jJQAryAyVq4</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>227000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Clinical Research Training Fellowship</gtr:description><gtr:end>2016-02-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>0D3F0868-9599-4C9E-8EA5-F937EAA8BA1C</gtr:id><gtr:outcomeId>bo1KTLvUAJD0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>260000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>CRUK Glasgow Centre Clinical Training Fellowship</gtr:description><gtr:end>2018-02-02</gtr:end><gtr:fundingOrg>Cancer Research UK</gtr:fundingOrg><gtr:id>5986087C-7A53-4C25-9B01-A154175F4DD0</gtr:id><gtr:outcomeId>54612fdb9c2573.63530771</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-02-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have generated a novel adenovirus vector that contains a DsRed tag on one of its minor capsid proteins. This means that we can track viral activity within infected cells and measure viral replication non-invasively within cells.</gtr:description><gtr:id>7373F8E1-594D-4E93-B74F-B734FCB9AA8A</gtr:id><gtr:impact>This vector allows longitudinal assessment of viral replication non-invasively and assessment of viral exit from infected cells, which is poorly understood. We will make this virus available to other researchers if desired. Manuscript is currently under review at Oncogene</gtr:impact><gtr:outcomeId>26C7F2DF4F0</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Ad5 dlCR2-dsRed</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>073D61E4-7BEC-45B4-BEDA-850D2C212124</gtr:id><gtr:title>Paclitaxel resistance increases oncolytic adenovirus efficacy via upregulated CAR expression and dysfunctional cell cycle control.</gtr:title><gtr:parentPublicationTitle>Molecular oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f629072a3f21edbe8442a4c333ed5d04"><gtr:id>f629072a3f21edbe8442a4c333ed5d04</gtr:id><gtr:otherNames>Ingemarsdotter CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1574-7891</gtr:issn><gtr:outcomeId>doi_55f984984310c2e6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>41A117B3-BC69-4731-87CF-524F689F289C</gtr:id><gtr:title>Current academic clinical trials in ovarian cancer: Gynecologic Cancer Intergroup and US National Cancer Institute Clinical Trials Planning Meeting, May 2009.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3e0a2b75a608e743f4188dad010ba00f"><gtr:id>3e0a2b75a608e743f4188dad010ba00f</gtr:id><gtr:otherNames>Trimble EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>qVKgttQD5L9</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>77E73E1F-5B75-4D57-9C2E-EF20B74345CD</gtr:id><gtr:title>Inhibition of the inflammatory cytokine TNF-a increases adenovirus activity in ovarian cancer via modulation of cIAP1/2 expression.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a468e59184e25256296033a3033450c2"><gtr:id>a468e59184e25256296033a3033450c2</gtr:id><gtr:otherNames>Salako MA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>cP23XEFkeTo</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>22029339-9EF3-4B72-BE7A-62BE1E1E1AFB</gtr:id><gtr:title>The intracellular uptake of CD95 modified paclitaxel-loaded poly(lactic-co-glycolic acid) microparticles.</gtr:title><gtr:parentPublicationTitle>Biomaterials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a4a54e7510f59f2cd19e061051e11c63"><gtr:id>a4a54e7510f59f2cd19e061051e11c63</gtr:id><gtr:otherNames>Ateh DD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0142-9612</gtr:issn><gtr:outcomeId>hJDcqvwhd6w</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AF6058AF-44C3-406B-A06C-7F25175FE9DF</gtr:id><gtr:title>Polo-like kinase Plk2 is an epigenetic determinant of chemosensitivity and clinical outcomes in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fdb8ace7901e715c0cb5bc22b90faaf1"><gtr:id>fdb8ace7901e715c0cb5bc22b90faaf1</gtr:id><gtr:otherNames>Syed N</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>aF2LfaFtAZF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BE598BB1-E3C6-4EE5-87A1-CF1BEC15389F</gtr:id><gtr:title>Nuclear survivin abrogates multiple cell cycle checkpoints and enhances viral oncolysis.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5624b0605b9308de726c7e3bd8507e37"><gtr:id>5624b0605b9308de726c7e3bd8507e37</gtr:id><gtr:otherNames>Connell CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56d405c41f0d41.82962856</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1D7D4476-9387-4B55-8B34-859820FF6D7A</gtr:id><gtr:title>Sequential genetic change at the TP53 and chemokine receptor CXCR4 locus during transformation of human ovarian surface epithelium.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dab73369afe0a89f2597d7de1f16039e"><gtr:id>dab73369afe0a89f2597d7de1f16039e</gtr:id><gtr:otherNames>Archibald KM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pm_15707_27_22266861</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>AA5D9343-EEBA-4ADC-BE4B-E29DE78C59C7</gtr:id><gtr:title>Arginine deprivation and argininosuccinate synthetase expression in the treatment of cancer.</gtr:title><gtr:parentPublicationTitle>International journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac09b7d03d3604b65f0d5b7a6bb85db0"><gtr:id>ac09b7d03d3604b65f0d5b7a6bb85db0</gtr:id><gtr:otherNames>Delage B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0020-7136</gtr:issn><gtr:outcomeId>dXHCSFN972D</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>8CF852F9-4B50-43EA-BE7A-6D05CD8EA859</gtr:id><gtr:title>CD40 ligand induced cytotoxicity in carcinoma cells is enhanced by inhibition of metalloproteinase cleavage and delivery via a conditionally-replicating adenovirus.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ea0ed0ef6b33132d55b70ba6c99f0bca"><gtr:id>ea0ed0ef6b33132d55b70ba6c99f0bca</gtr:id><gtr:otherNames>Elmetwali T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>JjSJJyR6HiN</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3948E1AC-21F0-4DC0-91FE-7EB4D433BAA6</gtr:id><gtr:title>Polo Like Kinase 2 Tumour Suppressor and cancer biomarker: new perspectives on drug sensitivity/resistance in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Oncotarget</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4aed63f50dafb5833405590be8b60b1a"><gtr:id>4aed63f50dafb5833405590be8b60b1a</gtr:id><gtr:otherNames>Coley HM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1949-2553</gtr:issn><gtr:outcomeId>pm_15707_27_22289679</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>66EBCE1D-45DC-4E8B-840E-E91D4882AF93</gtr:id><gtr:title>Rethinking ovarian cancer: recommendations for improving outcomes.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/986ed0b4f03a4d505348b2b881d0bb81"><gtr:id>986ed0b4f03a4d505348b2b881d0bb81</gtr:id><gtr:otherNames>Vaughan S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1474-175X</gtr:issn><gtr:outcomeId>NTVYUJwhHk6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4A1B2152-1312-4BD1-897A-9D4354A67273</gtr:id><gtr:title>&amp;quot;Re-educating&amp;quot; tumor-associated macrophages by targeting NF-kappaB.</gtr:title><gtr:parentPublicationTitle>The Journal of experimental medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/916556e206095ba8de824bfd28f7859f"><gtr:id>916556e206095ba8de824bfd28f7859f</gtr:id><gtr:otherNames>Hagemann T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0022-1007</gtr:issn><gtr:outcomeId>B44ED435FAF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3E933403-0245-4CC3-ADEF-75059FA45066</gtr:id><gtr:title>Targeted anti-vascular therapies for ovarian cancer: current evidence.</gtr:title><gtr:parentPublicationTitle>British journal of cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/781ccbfc4056954012e04c3a8a4c860b"><gtr:id>781ccbfc4056954012e04c3a8a4c860b</gtr:id><gtr:otherNames>Hall M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0007-0920</gtr:issn><gtr:outcomeId>pm_15707_27_23385789</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>987E9A34-A7EC-4A8F-A399-43298C607E26</gtr:id><gtr:title>The peritoneal tumour microenvironment of high-grade serous ovarian cancer.</gtr:title><gtr:parentPublicationTitle>The Journal of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f2e3f73fef7ddf148a790d78762c7669"><gtr:id>f2e3f73fef7ddf148a790d78762c7669</gtr:id><gtr:otherNames>Leinster DA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0022-3417</gtr:issn><gtr:outcomeId>pm_15707_27_22322968</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E3F27C04-21BC-4796-BDB8-93C0A5C6C223</gtr:id><gtr:title>Defining the surgical management of suspected early-stage ovarian cancer by estimating patient numbers through alternative management strategies.</gtr:title><gtr:parentPublicationTitle>BJOG : an international journal of obstetrics and gynaecology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/38f17532e294af6652ac8615e08f8302"><gtr:id>38f17532e294af6652ac8615e08f8302</gtr:id><gtr:otherNames>Warwick J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1470-0328</gtr:issn><gtr:outcomeId>FAC2917F011</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB322EAB-BD7B-4763-985E-B06D21E5DD20</gtr:id><gtr:title>Phase I/II study of oncolytic HSV GM-CSF in combination with radiotherapy and cisplatin in untreated stage III/IV squamous cell cancer of the head and neck.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b8dcd9a8ca9231cb47c4f3c4de48f137"><gtr:id>b8dcd9a8ca9231cb47c4f3c4de48f137</gtr:id><gtr:otherNames>Harrington KJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>TKbNPoJ2ypY</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>05B071B0-1C55-4F6D-995D-ABC4A0A2C8EF</gtr:id><gtr:title>Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f629072a3f21edbe8442a4c333ed5d04"><gtr:id>f629072a3f21edbe8442a4c333ed5d04</gtr:id><gtr:otherNames>Ingemarsdotter CK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>pgUsBpQddvc</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>6D3C427D-16B1-4582-A228-482390D09195</gtr:id><gtr:title>Genomic DNA damage and ATR-Chk1 signaling determine oncolytic adenoviral efficacy in human ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>The Journal of clinical investigation</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5624b0605b9308de726c7e3bd8507e37"><gtr:id>5624b0605b9308de726c7e3bd8507e37</gtr:id><gtr:otherNames>Connell CM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0021-9738</gtr:issn><gtr:outcomeId>56d405c1d5f9f7.40625509</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7B46A6A9-E278-4D0C-BC23-03CFCF30C4AD</gtr:id><gtr:title>Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Oncogene</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5a460ccf3c8751ea105f1d5a53e60a84"><gtr:id>5a460ccf3c8751ea105f1d5a53e60a84</gtr:id><gtr:otherNames>Baird SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0950-9232</gtr:issn><gtr:outcomeId>80489737AB6</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4D3F91CA-6FFB-45F0-AC74-A8732F1D9C44</gtr:id><gtr:title>Vaccinia virus induces programmed necrosis in ovarian cancer cells.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/26df6ecbbfa25d74e3babc1f779db156"><gtr:id>26df6ecbbfa25d74e3babc1f779db156</gtr:id><gtr:otherNames>Whilding LM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_15707_27_23985697</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E9CCB93A-D8DB-461A-8047-F18ED177DE61</gtr:id><gtr:title>Proinflammatory characteristics of SMAC/DIABLO-induced cell death in antitumor therapy.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7042fb5eef009886b71455a5e8e5b3f5"><gtr:id>7042fb5eef009886b71455a5e8e5b3f5</gtr:id><gtr:otherNames>Emeagi PU</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>pm_15707_27_22379024</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>04FC9316-3F12-4005-9769-7C0813C6E6DC</gtr:id><gtr:title>Failure of translation of human adenovirus mRNA in murine cancer cells can be partially overcome by L4-100K expression in vitro and in vivo.</gtr:title><gtr:parentPublicationTitle>Molecular therapy : the journal of the American Society of Gene Therapy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3457936797ccbfd7d9ba22f0029cdf0e"><gtr:id>3457936797ccbfd7d9ba22f0029cdf0e</gtr:id><gtr:otherNames>Young AM</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1525-0016</gtr:issn><gtr:outcomeId>pm_15707_27_22735379</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37BDFFD5-F12D-4914-A283-DE0D09990B49</gtr:id><gtr:title>Oncolytic adenoviral gene therapy in ovarian cancer: why we are not wasting our time.</gtr:title><gtr:parentPublicationTitle>Future oncology (London, England)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/277ebb056350b951dee9045161b28bb0"><gtr:id>277ebb056350b951dee9045161b28bb0</gtr:id><gtr:otherNames>Young A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>1479-6694</gtr:issn><gtr:outcomeId>56d405c3eb9526.69528910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DC6E0001-4FC3-420C-A422-56E67C5F8F39</gtr:id><gtr:title>In vivo retargeting of adenovirus type 5 to alphavbeta6 integrin results in reduced hepatotoxicity and improved tumor uptake following systemic delivery.</gtr:title><gtr:parentPublicationTitle>Journal of virology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/59e40beb6fed2d4f243b2d51c02a088b"><gtr:id>59e40beb6fed2d4f243b2d51c02a088b</gtr:id><gtr:otherNames>Coughlan L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0022-538X</gtr:issn><gtr:outcomeId>39387F9084B</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1F38B60B-1F12-4FD8-8FEA-ADA62E5157CE</gtr:id><gtr:title>Interleukin-6 as a therapeutic target in human ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Clinical cancer research : an official journal of the American Association for Cancer Research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7c9c1dac2bfb471e420a214860155f02"><gtr:id>7c9c1dac2bfb471e420a214860155f02</gtr:id><gtr:otherNames>Coward J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1078-0432</gtr:issn><gtr:outcomeId>aD3MtZedjiF</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>ABF3685D-AC16-4C07-B112-99D6968313E5</gtr:id><gtr:title>Primary chemotherapy for inoperable ovarian, fallopian tube, or primary peritoneal cancer with or without delayed debulking surgery.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/894b54d8f6f213ece43de16a736506be"><gtr:id>894b54d8f6f213ece43de16a736506be</gtr:id><gtr:otherNames>Saha A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>pm_15707_27_22426404</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D766BD51-056E-4CD9-9AB0-DD1D34805FDB</gtr:id><gtr:title>Role of molecular agents and targeted therapy in clinical trials for women with ovarian cancer.</gtr:title><gtr:parentPublicationTitle>International journal of gynecological cancer : official journal of the International Gynecological Cancer Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1fe5554178ca2cb19c4c96c065d6389"><gtr:id>f1fe5554178ca2cb19c4c96c065d6389</gtr:id><gtr:otherNames>Ledermann JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1048-891X</gtr:issn><gtr:outcomeId>ib2vAEFgJ3o</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37815FAD-B03A-4D47-9EFA-3CA07307BEBD</gtr:id><gtr:title>Paraneoplastic thrombocytosis in ovarian cancer.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3d05bf6b6f0ea3603306e5ba353c5cf2"><gtr:id>3d05bf6b6f0ea3603306e5ba353c5cf2</gtr:id><gtr:otherNames>Stone RL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_15707_27_22335738</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4EB1DA84-8206-4B5A-9B54-21D5511A783B</gtr:id><gtr:title>Pharmacological Inhibition of ?3 Integrin Reduces the Inflammatory Toxicities Caused by Oncolytic Adenovirus without Compromising Anticancer Activity.</gtr:title><gtr:parentPublicationTitle>Cancer research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3eefbf56e8a0778017ec20eb605626ab"><gtr:id>3eefbf56e8a0778017ec20eb605626ab</gtr:id><gtr:otherNames>Browne A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0008-5472</gtr:issn><gtr:outcomeId>56d405be40eee8.43562746</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FB99A928-02A5-4F2B-9C08-12B6314E146C</gtr:id><gtr:title>Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.</gtr:title><gtr:parentPublicationTitle>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1fe5554178ca2cb19c4c96c065d6389"><gtr:id>f1fe5554178ca2cb19c4c96c065d6389</gtr:id><gtr:otherNames>Ledermann JA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>0732-183X</gtr:issn><gtr:outcomeId>bReTCeCqyHs</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>1FD633BF-DA3B-49A9-A1A0-0D7AD26130D8</gtr:id><gtr:title>Assessment of the Na/I symporter as a reporter gene to visualize oncolytic adenovirus propagation in peritoneal tumours.</gtr:title><gtr:parentPublicationTitle>European journal of nuclear medicine and molecular imaging</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/1a9ff59288783ab26e03c2e293d41b9b"><gtr:id>1a9ff59288783ab26e03c2e293d41b9b</gtr:id><gtr:otherNames>Merron A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1619-7070</gtr:issn><gtr:outcomeId>pvSujyLbiLg</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EB551825-F907-46B3-B9B0-CF32145642C2</gtr:id><gtr:title>Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition).</gtr:title><gtr:parentPublicationTitle>Autophagy</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3338e204a3c58e1fab88cb3342a71645"><gtr:id>3338e204a3c58e1fab88cb3342a71645</gtr:id><gtr:otherNames>Klionsky DJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1554-8627</gtr:issn><gtr:outcomeId>56d408dabeafd3.70833955</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CB953C2-73BD-4FCA-9C1D-93FE4CA476E0</gtr:id><gtr:title>p21 Promotes oncolytic adenoviral activity in ovarian cancer and is a potential biomarker.</gtr:title><gtr:parentPublicationTitle>Molecular cancer</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7ae38f4230ee7fff590c132d18ee916f"><gtr:id>7ae38f4230ee7fff590c132d18ee916f</gtr:id><gtr:otherNames>Flak MB</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:issn>1476-4598</gtr:issn><gtr:outcomeId>dBTsHUHLyXe</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>46E554C3-FE93-47A2-827B-32B70D810156</gtr:id><gtr:title>RAD51 and BRCA2 Enhance Oncolytic Adenovirus Type 5 Activity in Ovarian Cancer.</gtr:title><gtr:parentPublicationTitle>Molecular cancer research : MCR</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9b310ea4382b44def9b9c9af2fff8705"><gtr:id>9b310ea4382b44def9b9c9af2fff8705</gtr:id><gtr:otherNames>Tookman LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1541-7786</gtr:issn><gtr:outcomeId>56d408dbe58484.56894678</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0601891</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>7C58A707-1BF6-4573-A44F-30B271C80813</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Cancer</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>DD81206B-5EB4-4BCC-AEF7-808A64606E0E</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.2  Cellular and gene therapies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>